– UK, Cambridge – Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr. John Montana, Ph.D., to its Board as a Non-Executive Director.
“I am pleased to welcome John Montana to Metrion Biosciences’ board of directors. John brings substantial experience of building effective scientific CRO operations as well as a successful track record in drug discovery. He will be an asset to Metrion’s Board and contribute significantly to the Company’s further growth and international development.” said Board Chairman, Dr Keith McCullagh.
About Dr. John Montana
Dr Montana brings over 30 years’ drug discovery and development experience across the pharmaceutical, biotech, and contract research sectors. Dr. Montana is currently an Operating Partner at Forbion, the life science venture capital firm. His previous roles have included Corporate VP, Integrated Drug Discovery, at Charles River Labs, as well as multiple C-suite positions such as CSO at Argenta, CEO of Amedis, Head of Chemistry at Chiroscience, and various roles at GlaxoSmithKline.
Dr. John Montana commented: “I am delighted to be joining Metrion at such an exciting time for the Company. Metrion has established itself as a leader in the ion channel contract research and drug discovery space and I look forward to joining the team and the Board on this journey, working together to extend Metrion’s capabilities.”
Dr. Montana holds a BSc in Chemistry from The University of Manchester and a Ph.D. in Medicinal Chemistry from the University of East Anglia.
For more information: https://www.metrionbiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.